The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
Open accessAbstract
Engagement of the B7 family of molecules on antigen-presenting cells with their T cell-associated ligands, CD28 and CD152 (cytotoxic T lymphocyte-associated antigen-4 [CTLA-4]), provides a pivotal costimulatory signal in T-cell activation. We investigated the role of the CD28/CD152 pathway in psoriasis in a 26-week, phase I, open-label dose-escalation study. The importance of this pathway in the generation of humoral immune responses to T cell-dependent neoantigens, bacteriophage phiX174 and keyhole limpet hemocyanin, was also evaluated. Forty-three patients with stable psoriasis vulgaris received 4 infusions of the soluble chimeric protein CTLA4Ig (BMS-188667). Forty-six percent of all study patients achieved a 50% or greater sustained improvement in clinical disease activity, with progressively greater effects observed in the highest-dosing cohorts. Improvement in these patients was associated with quantitative reduction in epidermal hyperplasia, which correlated with quantitative reduction in skin-infiltrating T cells. No markedly increased rate of intralesional T-cell apoptosis was identified, suggesting that the decreased number of lesional T cells was probably likely attributable to an inhibition of T-cell proliferation, T-cell recruitment, and/or apoptosis of antigen-specific T cells at extralesional sites. Altered antibody responses to T cell-dependent neoantigens were observed, but immunologic tolerance to these antigens was not demonstrated. This study illustrates the importance of the CD28/CD152 pathway in the pathogenesis of psoriasis and suggests a potential therapeutic use for this novel immunomodulatory approach in an array of T cell-mediated diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., & Stein, H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1710 · Cited by 4,173
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
Self-citationMueller, D. L., Jenkins, M. K., & Schwartz, R. H. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.002305 · Cited by 1,493
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL
Boise, L. H., Minn, A. J., Noel, P. J., June, C. H., Accavitti, M. A., Lindsten, T., & Thompson, C. B. (1995) · Immunity · doi:10.1016/1074-7613(95)90161-2 · Cited by 1,210
Linsley, P. S., Brady, W., Grosmaire, L., Aruffo, A., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.721 · Cited by 1,127
Self-citationLong-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lg
Lenschow, D. J., Zeng, Y., Thistlethwaite, J. R., Montag, A., Brady, W., Gibson, M. G., Linsley, P. S., & Bluestone, J. A. (1992) · Science · doi:10.1126/science.1323143 · Cited by 1,121
Self-citationT Cell Activation Determined by T Cell Receptor Number and Tunable Thresholds
Viola, A., & Lanzavecchia, A. (1996) · Science · doi:10.1126/science.273.5271.104 · Cited by 1,023
Krummel, M. F., & Allison, J. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2533 · Cited by 932
Cited by
Pathogenesis and therapy of psoriasis
Lowes, M. A., Bowcock, A. M., & Krueger, J. G. (2007) · Nature · doi:10.1038/nature05663 · Cited by 1,778
Self-citationLowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120225 · Cited by 1,650
Self-citationCo-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Davidson, A., & Diamond, B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108023450506 · Cited by 1,042
Complexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and Transplantation
Salomon, B., & Bluestone, J. A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.225 · Cited by 1,006
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
Psoriasis pathogenesis and the development of novel targeted immune therapies
Hawkes, J. E., Chan, T. C., & Krueger, J. G. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.004 · Cited by 972
Self-citationVincenti, F., Charpentier, B., Vanrenterghem, Y., Rostaing, L., Bresnahan, B., Darji, P., Massari, P., Mondragon‐Ramirez, G. A., Agarwal, M., Di Russo, G., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03005.x · Cited by 957
Effector and Memory CTL Differentiation
Williams, M. A., & Bevan, M. J. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141548 · Cited by 949
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60886-6 · Cited by 612
The immunologic basis for the treatment of psoriasis with new biologic agents
Krueger, J. G. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120568 · Cited by 600
Self-citationLebwohl, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12954-6 · Cited by 548
Self-citationGetting under the skin: the immunogenetics of psoriasis
Bowcock, A. M., & Krueger, J. G. (2005) · Nature Reviews Immunology · doi:10.1038/nri1689 · Cited by 484
Self-citationShanahan, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07284-7 · Cited by 478
Zaba, L. C., Fuentes-Duculan, J., Eungdamrong, N. J., Abello, M. V., Novitskaya, I., Pierson, K. C., Gonzalez, J., Krueger, J. G., & Lowes, M. A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.194 · Cited by 442
Self-citationKimball, A. B., Gladman, D., Gelfand, J. M., Gordon, K., Horn, E. J., Korman, N. J., Korver, G., Krueger, G. G., Strober, B. E., & Lebwohl, M. G. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.01.006 · Cited by 432
Self-citationBour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391
Organ transplantation—how much of the promise has been realized?
Lechler, R. I., Sykes, M., Thomson, A. W., & Turka, L. A. (2005) · Nature Medicine · doi:10.1038/nm1251 · Cited by 390
CD3-specific antibodies: a portal to the treatment of autoimmunity
Chatenoud, L., & Bluestone, J. A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2134 · Cited by 388
Moreland, L. W., Alten, R., Van Den Bosch, F., Appelboom, T., Leon, M., Emery, P., Cohen, S., Luggen, M., Shergy, W., Nuamah, I., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10294 · Cited by 383
CD28, CTLA‐4 and their ligands: who does what and to whom?
Sansom, D. M. (2000) · Immunology · doi:10.1046/j.1365-2567.2000.00121.x · Cited by 362
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution
Kuek, A., Hazleman, B. L., & Östör, A. J. K. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2006.052688 · Cited by 335
The Immunopathogenesis of Psoriasis
Kim, J., & Krueger, J. G. (2015) · Dermatologic Clinics · doi:10.1016/j.det.2014.09.002 · Cited by 331
Self-citationScanning the Immunopathogenesis of Psoriasis
Chiricozzi, A., Romanelli, P., Volpe, E., Borsellino, G., & Romanelli, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010179 · Cited by 320
Abrams, J. R., Kelley, S. L., Hayes, E., Kikuchi, T., Brown, M. J., Kang, S., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Linsley, P. S., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.5.681 · Cited by 318
Self-citationSonkoly, E., Janson, P., Majuri, M.-L., Savinko, T., Fyhrquist, N., Eidsmo, L., Xu, N., Meisgen, F., Wei, T., Bradley, M., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.05.045 · Cited by 317
Conrad, C., Di Domizio, J., Mylonas, A., Belkhodja, C., Demaria, O., Navarini, A. A., Lapointe, A.-K., French, L. E., Vernez, M., & Gilliet, M. (2018) · Nature Communications · doi:10.1038/s41467-017-02466-4 · Cited by 317
Importance of ICOS–B7RP-1 costimulation in acute and chronic allograft rejection
Özkaynak, E., Gao, W., Shemmeri, N., Wang, C., Gutierrez-Ramos, J.-C., Amaral, J., Qin, S., Rottman, J. B., Coyle, A. J., & Hancock, W. W. (2001) · Nature Immunology · doi:10.1038/89731 · Cited by 317
Mease, P., Genovese, M. C., Gladstein, G., Kivitz, A. J., Ritchlin, C., Tak, P. P., Wollenhaupt, J., Bahary, O., Becker, J., Kelly, S., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30176 · Cited by 300
Lew, W., Bowcock, A. M., & Krueger, J. G. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.03.006 · Cited by 284
Self-citationCD86 and CD80 Differentially Modulate the Suppressive Function of Human Regulatory T Cells
Zheng, Y., Manzotti, C. N., Liu, M., Burke, F., Mead, K. I., & Sansom, D. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2778 · Cited by 279
CTLA4Ig: Bridging the Basic Immunology with Clinical Application
Bluestone, J. A., St. Clair, E. W., & Turka, L. A. (2006) · Immunity · doi:10.1016/j.immuni.2006.03.001 · Cited by 276
Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 259
Tarcha, E. J., Olsen, C. M., Probst, P., Peckham, D., Muñoz-Elías, E. J., Kruger, J. G., & Iadonato, S. P. (2017) · PLOS ONE · doi:10.1371/journal.pone.0180762 · Cited by 167
Inflammation in multiple sclerosis: the good, the bad, and the complex
Martino, G., Adorini, L., Rieckmann, P., Hillert, J., Kallmann, B., Comi, G., & Filippi, M. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00223-5 · Cited by 142
Andreadis, S. T., Hamoen, K. E., Yarmush, M. L., & Morgan, J. R. (2001) · The FASEB Journal · doi:10.1096/fsb2fj000324com · Cited by 147
“Clearly the immune system plays a critical role in this disease ( 42 ); however, the nature of the molecular signals that activates the epidermis to undergo such significant changes to proliferation and cell‐ cell organization is largely unknown.”
BackgroundRNA interference of sialidase improves glycoprotein sialic acid content consistency
Ngantung, F. A., Miller, P. G., Brushett, F. R., Tang, G. L., & Wang, D. I. C. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20997 · Cited by 97
Alten, R., Bingham, C. O., Cohen, S. B., Curtis, J. R., Kelly, S., Wong, D., & Genovese, M. C. (2016) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-016-1082-z · Cited by 75
“The primary pre-specified efficacy endpoint for the pneumococcal sub-study was the proportion of patients achieving an immunologic response, defined as a ≥2-fold increase in post-vaccination titers to ≥3 of 5 antigens (9V, 14, 18C, 19F, and 23F) [18, 21, 23, 29, 30, 32] at Day 28, in patients without a protective anti…”
MethodInfluential
Metadata
- Authors
- Abrams, J. R., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Goldfarb, M. T., Goffe, B. S., Menter, A., Lowe, N. J., Krueger, G., Brown, M. J., Weiner, R. S., Birkhofer, M. J., Warner, G. L., Berry, K. K., Linsley, P. S., Krueger, J. G., Ochs, H. D., Kelley, S. L., & Kang, S.
- Venue
- Journal of Clinical Investigation
- Published
- 1999-05-01
- Volume
- 103
- Issue
- 9
- Pages
- 1243-1252
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2137096190
- Cited by
- 597
- References
- 49
- FWCI
- 15.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.